Back to results
US 12,552,775 B2Granted
Compounds and uses thereof
AssigneeFoghorn Therapeutics Inc.
InventorsMatthew Netherton, Francois Brucelle, Jing Deng, Johannes H. Voigt
Life of this patent
Estimating the term…
Abstract
The present disclosure features compounds and methods useful for the treatment of BAF complex-related disorders.
Claims29
A compound having the structure of Formula I:
- wherein
- X is halo;
- X1 is absent, O, or NR1;
- k is 0, 1, 2, or 3;
- n is 0, 1, or 2;
- R1 is H or optionally substituted C1-C6 alkyl;
- L1 is optionally substituted C1-C6 alkylene, optionally substituted C2-C6 alkenylene, or optionally substituted C2-C6 alkynylene;
- L2 is absent, optionally substituted C1-C6 alkylene, optionally substituted C1-C20 heteroalkylene, or optionally substituted C2-C9 heterocyclylene;
- each L3 is, independently, optionally substituted C1-C20 heteroalkylene, optionally substituted C3-C10 carbocyclylene, optionally substituted C3-C10 carbocyclylene-C1-C6 alkylene, optionally substituted C2-C9 heterocyclylene, optionally substituted C2-C9 heterocyclylene-C1-C6 alkylene, optionally substituted C6-C10 arylene, optionally substituted C6-C10 arylene-C1-C6 alkylene, optionally substituted C2-C6 alkynylene, O, or NR1;
- and
- D is a degradation moiety,
- or a pharmaceutically acceptable salt thereof.
9 more elements
A compound selected from the group consisting of compounds 1-105 in Table 1 and pharmaceutically acceptable salts thereof.
Dependencies are inferred from the claim text.